Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers September 6, 2023
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers September 6, 2023
CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine September 1, 2023
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers September 1, 2023
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience August 23, 2023
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy August 16, 2023
Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics August 9, 2023
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation ADCs August 2, 2023
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours August 2, 2023
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets August 2, 2023
Enhertu demonstrated clinically meaningful PFS and OS across multiple HER2-expressing advanced solid tumours in DESTINY-PanTumor02 Phase II trial August 2, 2023
AbbVie terminated a 2020 collaboration with Jacobio Pharmaceuticals centred on the development and commercialisation of SHP2 inhibitors July 19, 2023
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors July 19, 2023
F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies July 12, 2023
Paxalisib Receives Fast Track Designation From FDA For Treatment Of Solid Tumor Brain Mets Harboring PI3K Pathway Mutations In Combination With Radiation Therapy July 11, 2023
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® and Novel ADC Candidates for Advanced Solid Tumors in China July 5, 2023
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for R/R Advanced Solid Tumors July 5, 2023
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders June 21, 2023
Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours June 14, 2023
